NaHS treatment could improve cardiac function by targeting ROS and autophagic activities in a mouse DCM model through the elevation of Kelch-like ECH associated protein 1 (Keap-1) expression [187]. Here, KEAP1 is linked to familial dilated cardiomyopathy.